<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04462068</url>
  </required_header>
  <id_info>
    <org_study_id>SAR3</org_study_id>
    <nct_id>NCT04462068</nct_id>
  </id_info>
  <brief_title>ACE and HLA Genotypes Predict Severity and Disease Progression in Danish Sarcoid Patients</brief_title>
  <official_title>ACE and HLA Genotypes Predict Severity and Disease Progression in Danish Sarcoid Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcoidosis is a multisystem granulomatous disease of unknown cause histologically
      characterized by noncaseating granulomas. Genetic factors affect disease course, which is
      highly variable and difficult to predict.

      This study aims to evaluate the predictive value of ACE and HLA genotypes on disease severity
      and progression in Danish patients with sarcoidosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to initiation of treatment</measure>
    <time_frame>1 year from diagnosis</time_frame>
    <description>Time to initiation of systemic immunosuppression for sarcoidosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with extrapulmonary organ involvement</measure>
    <time_frame>1 year from diagnosis</time_frame>
    <description>Number of participants diagnosed with extrapulmonary organ involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>1 year</time_frame>
    <description>Increase/ decline/ no change in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC</measure>
    <time_frame>1 year</time_frame>
    <description>Increase/ decline/ no change in FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diffusion capacity</measure>
    <time_frame>1 year</time_frame>
    <description>Increase/ decline/ no change in diffusion capacity</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sarcoidosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with sarcoidosis seen in Department of Respiratory Diseases, Aarhus Denmark
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of sarcoidosis

          -  Signed informed consent

        Exclusion Criteria:

          -  Inability or unwillingness to adhere to the study

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aarhus University Hospital. Dep. of Respiatory Diseases and Allergology</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janne MÃ¸ller, MD</last_name>
      <phone>0045 78462201</phone>
      <email>jannmoel@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>July 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

